< 1 minute read
Dec. 10, 2021

Repotrectinib (TPX-0005): A Brain-Penetrant Macrocyclic ALK/ROS1/TRK Kinase Inhibitor

repotrectinib

oral, CNS-penetrant TRK(A-C) kinase inhibitor Ph. II candidate for solid tumors (160 mg QD), approved 2023 from literature starting point Molecular Cancer Therapeutics Turning Point Therapeutics, San Diego, CA

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in